Patents by Inventor Candy N. Lee

Candy N. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8486392
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: July 16, 2013
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Paul Moore, Tao He, Candy N. Lee, Karen Van Orden
  • Patent number: 8334106
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: December 18, 2012
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Candy N. Lee, Bruno Domon
  • Publication number: 20120177659
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Application
    Filed: December 29, 2011
    Publication date: July 12, 2012
    Applicant: CELERA CORPORATION
    Inventors: Steve RUBEN, Karen VAN ORDEN, Candy N. LEE, Tao HE, Mehdi MESRI, Elizabeth G. JOSELOFF, Paul MOORE, Katherine MCKINNON, Bruno DOMON
  • Patent number: 8110373
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: February 7, 2012
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Candy N. Lee, Bruno Domon
  • Publication number: 20110250204
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Application
    Filed: October 8, 2010
    Publication date: October 13, 2011
    Applicant: CELERA CORPORATION
    Inventors: Steve RUBEN, Paul A. MOORE, Tao HE, Candy N. LEE, Karen VAN ORDEN, Charles E. Birse, Mehdi Mesri, Elizabeth G. Joseloff
  • Patent number: 7842291
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: November 30, 2010
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Paul A. Moore, Tao He, Candy N. Lee, Karen Van Orden, Charles E. Birse, Mehdi Mesri, Elizabeth G. Joseloff
  • Publication number: 20100061977
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Application
    Filed: July 17, 2009
    Publication date: March 11, 2010
    Applicant: CELERA CORPORATION
    Inventors: Steve RUBEN, Karen VAN ORDEN, Candy N. LEE, Tao HE, Mehdi MESRI, Elizabeth G. JOSELOFF, Paul MOORE, Katherine MCKINNON, Bruno DOMON
  • Patent number: 7582441
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: September 1, 2009
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Candy N. Lee, Bruno Domon